APA (7th ed.) Citation

Fizazi, K., Retz, M., Petrylak, D. P., Goh, J. C., Perez-Gracia, J., Lacombe, L., . . . Pachynski, R. K. (2022). Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: Results from the phase 2 CheckMate 9KD trial. Journal for ImmunoTherapy of Cancer, 10(8), . https://doi.org/10.1136/jitc-2022-004761

Chicago Style (17th ed.) Citation

Fizazi, Karim, et al. "Nivolumab Plus Rucaparib for Metastatic Castration-resistant Prostate Cancer: Results from the Phase 2 CheckMate 9KD Trial." Journal for ImmunoTherapy of Cancer 10, no. 8 (2022). https://doi.org/10.1136/jitc-2022-004761.

MLA (9th ed.) Citation

Fizazi, Karim, et al. "Nivolumab Plus Rucaparib for Metastatic Castration-resistant Prostate Cancer: Results from the Phase 2 CheckMate 9KD Trial." Journal for ImmunoTherapy of Cancer, vol. 10, no. 8, 2022, https://doi.org/10.1136/jitc-2022-004761.